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Adjuvant chemotherapy has become a standard of care in patients with early stage colon
cancer. 5-Fluorouracil modulated by leucovorin is the mainstay of treatment, but it has
evolved from the bolus administration to continuous infusion and combination therapy.
Oral fluoropyrimidines may be an alternative to bolus 5-fluorouracil plus folinic acid. The
benefit of adjuvant therapy is established in stage III colon cancer, whereas in stage II
the evidence supporting the adjuvant therapy is still poor. Current issues concern the dura-
tion of treatment, the development of new schedules and strategies including biological
agents and the identification of prognostic and predictive biological markers.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Since the early 1990s, adjuvant chemotherapy was recom-
mended as a treatment for stage III colon cancer, following
the pioneer studies of Wolmark et al. and of Moertel et al.1,2
However, amongst the drugs used in those trials, only 5-fluo-
uracil (FU) is still the mainstay of colon cancer adjuvant ther-
apy. Levamisole is no longer recommended as its role is
unclear, whereas the subsequent studies in the United States
(US) and Europe have established the role of the biomodula-
tion of FU with folinic acid (leucovorin, LV). A statistically sig-
nificant improvement in disease-free (DFS) and overall
survival (OS) was confirmed in all patients receiving adjuvant
therapy.3 None of the two more used schedule of bolus FU in
combination with LV (Mayo Clinic or Roswell Park schedules)
resulted superior nor high dose compared to low dose LV.4–7
Furthermore, other potential modulators of FU, such as meth-
otrexate (MTX) or interferon (IFN) added some toxic effect but
no clinical benefit, compared to the combination of bolus FU
and LV. Therefore, this combination, whatever the schedule
(Mayo Clinic or Roswell Park), became the standard adjuvant
chemotherapy for colon cancer up to the first 2000s.er Ltd. All rights reserved
t2. Refinement of fluoropyrimidine
monotherapy
Following the improved survival with reduction of some
toxic effect observed in advanced colorectal cancer (CRC)
through the administration of FU by continuous infusion,
these regimens were also evaluated in the adjuvant
setting.8,9 None of the trials found a significant benefit in fa-
vour of the infusional schedule, but the patients treated with
continuous infusion FU had less toxicity compared with the
patients treated with bolus FU. As a result, in Europe the
hybrid semimonthly LV5FU2 schedule became the compara-
tor arm in trials evaluating the combination therapy in the
adjuvant setting.
The continuous FU infusion carries the need of indwelling
intravenous catheters and infusion pump as well as raises the
risk of catheter contamination and thrombosis. For this rea-
son, oral fluoropyrimidines were developed with the aim of
avoiding these risks meanwhile preserving the improved tol-
erability of continuous infusion. The X-ACT trial randomised
patients with stage III colon cancer to capecitabine (XEL) or
bolus FU/LV (Mayo Clinic) and showed that XEL was at least
equivalent to bolus FU as far as DFS (the primary end-point)
and OS were concerned.10 Hand–foot syndrome and hyperbil-
irubinemia aside, the safety profile was more favourable with
XEL. An equivalence in DFS and OS with similar toxicity was.
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covorin in comparison to the Roswell Park regimen.113. Combination therapy
Amajor change in survival of patients with advanced colorec-
tal cancer came at the end of 1990s with the addition of l-Oxa-
liplatin (OXA) and Irinotecan (IRI) to FU/LV, in particular to the
hybrid regimen LV5FU2. The same combination regimens
were therefore translated into the adjuvant treatment.
The addition of OXA to FU/LV was first shown to be bene-
ficial by the European MOSAIC trial, which included 2246
stages II and III patients with the primary end-point of
improving DFS. The 3-year DFS was significantly higher with
FOLFOX than with LV5FU2 (78.2% versus 70.2%; p = 0.002); this
translates as a 23% reduction in the risk of recurrence.12 A re-
cent update confirmed the significant difference (5-year DFS
73.3% versus 67.4%; p = 0.003) and the reduction in the risk
of recurrence.13 The analysis by stage showed a statistically
significant improvement in DFS only for stage III patients.
After 6 years of follow-up a statistically significant OS benefit
(73% versus 68.6%; p = 0.029) was confirmed in stage III sub-
group, but not in stage II subgroup nor for the overall patient
population. The results obtained in the MOSAIC study have
been confirmed by another large trial, the US NSABP C-07,
which randomised 2407 stages II and III patients to bolus
FU/LV or to the same regimen with OXA.14 The 3-year DFS
was significantly improved with combination treatment
(76.1% versus 71.8%). In both studies the OXA-related periph-
eral neuropathy was a not irrelevant concern, not only for its
incidence or severity, but especially for the persistence; in the
MOSAIC study grades 1–2 neuropathy was still present in 15%
of patients after 4 years of follow-up and in NSABP C-07 it per-
sisted in more than 10% of patients for over 2 years.
Following the development of capecitabine as an alterna-
tive to bolus FU/LV in the adjuvant therapy and its established
efficacy in combination with OXA in advanced CRC, a trial has
been conducted comparing XEL plus OXAwith bolus FU/LV as
adjuvant therapy in stage III colon cancer. The planned safety
analysis has been recently reported, that demonstrates that
XELOX has a manageable tolerability profile; however, the fea-
tures of the comparator arm should not be overlooked. Effi-
cacy data will be available in the next year.
Taking into account its efficacy in advanced CRC, the not
favourable results of the addition of IRI to FU/LV are surpris-
ing. The CALGB 89803 study comparing bolus FU/LV plus IRI
(IFL) with the same combination without IRI was prematurely
closed due to an excess of 60-day all-cause mortality in the
IFL arm (2.5% versus 0.8%).15 The combination of IRI with
LV5FU2 (FOLFIRI), which has an established efficacy in ad-
vanced disease, was compared to LV5FU2 in the European PE-
TACC-3 study with DFS as primary end-point. The 3-year DFS
resulted higher in the experimental arm, but not significant
(63.3% versus 60.3%; p = 0.09).16 The reasons for the failure
of these trials and for their poorer survivals are unknown,
but could be attributable – at least in part – to the trial design
or the IRI regimen used by some of these trials. In the PE-
TACC-3 study, in fact, the definition of DFS is different from
that used in the MOSAIC trial. Provided that the relapse freesurvival (RFS) in the PETACC-3 study matches with DFS in
the MOSAIC study, the RFS difference between FOLFIRI and
LV5FU2 in the PETACC-3 study becomes borderline statisti-
cally significant in favour of the experimental arm.4. End-points
Although the improvement in OS seems the most appropriate
end-point in order to demonstrate a benefit from adjuvant
therapy, it might be heavily influenced by progress in the
treatment of metastatic CRC. Furthermore, the evaluation of
OS requires a long time compared to the development of
knowledge in this field. For this reason in the last decade
there has been a move toward using surrogate end-points
such as DFS, that combines the advantage of being evaluable
more rapidly and of being unaffected by post-relapse treat-
ment. Its predictive potential for OS is accepted by most
authors.
The Adjuvant Colon Cancer End Points (ACCENT) group
has analysed the pooled individual data of 20,898 patients
from 18 randomised controlled trials of adjuvant colon cancer
therapy consisting of FU with either LV or levamisole, demon-
strating that 3-year DFS correlates with 5-year survival.17 The
correlation is stronger in stage III than in stage II disease. In
this analysis, DFS was defined as the time from randomisa-
tion to the first event of either recurrent disease or death from
any cause, excluding the occurrence of second primary tu-
mours as events. However, in some studies, such as the PE-
TACC-3, this definition corresponds to RFS, whereas DFS
included second primary cancer, colonic or not. Actually,
the definition of DFS was a critical point. In fact, the study
did not meet the primary end-point of improving DFS, but
there was a significant improvement of RFS, which was a sec-
ondary end-point.
The ACCENT Group study has validated the use of DFS as
primary end-point in the place of OS; however, it should be
remembered that the definition of events used might prevent
the capture of the possibility of treatment-related second
malignancies.5. Stage II colon cancer
Stage II patients have a lower risk of relapse compared with
stage III patients. Therefore, any incremental benefit from
adjuvant treatment is likely to be proportionally smaller in
magnitude and this means that a larger number of patients
would be required for adequate statistical power in compari-
son with stage III. Actually, many studies powered for show-
ing a benefit in stage III have also included stage II patients.
For example, in the MOSAIC study separate analyses were
planned for the stage II subgroup, but they failed to reach
the statistical significance. Similarly, a trial which random-
ised 500 stage II patients between FU/LV and observation
has not found any significant difference in OS and DFS be-
tween the two arms.18
The largest randomised study of patients with stage II dis-
ease is the Quick And Simple And Reliable (QUASAR) ‘uncer-
tain indication’ trial.19 In this trial, 3239 patients were
enrolled in whom the role of adjuvant chemotherapy was
62 E J C S U P P L E M E N T S 6 ( 2 0 0 8 ) 6 0 –6 3considered uncertain by the treating physician. The patients
were randomised between observation and different sched-
ules of FU/LV ± levamisole. The study demonstrated a signifi-
cantly reduced recurrence (risk ratio 0.78; p = 0.001) and
improved survival (risk ratio 0.82; p = 0.008) in favour of the
treatment arm. The results should be interpreted prudently
because of the heterogeneity of study population, treatment
and follow-up.
Amongst the metanalyses that addressed this issue, that
performed by the Cancer Care Ontario Programme (CCOP), in-
cluded 4187 patients with stage II colon cancer showing a
marginal not significant benefit for treated patients.20 Based
in part on these results, the ASCO issued guidelines recom-
mending that adjuvant chemotherapy should be considered
only in stage II patients having high-risk disease defined by
the presence of at least one of the following features: T4 tu-
mors, poorly differentiated histology, presentation with per-
foration or inadequate sampling (<13) of lymph nodes.21
Noteworthy, the high-risk stage II patients in the MOSAIC trial
were defined according to different criteria than that used in
the ASCO guidelines.6. Timing and duration of treatment
There are data to suggest that benefits from adjuvant treat-
ment are reduced if treatment is delayed by more than 8
weeks after surgery. An analysis of patients with stage III co-
lon cancer who received adjuvant chemotherapy and were
recordered within the US ‘Surveillance, Epidemiology, End Re-
sults’ (SEER)-Medicare database found that a delay in com-
mencement of treatment, defined as 3 or more months after
surgery, was associated with an increase in colon cancer-spe-
cific mortality.22 However, due to retrospective nature of the
study, it is unknown if the reasons of the delay were related
to the clinical conditions of patients.
As far the issue of treatment duration, there is no evidence
that there is any additional benefit from treatment with FU/LV
for longer than 6 months. On the other hand, the SAFFA ran-
domised study demonstrated that 12 weeks of protracted ve-
nous infusion of FU is as effective as 6 months of bolus FU/
LV.23 Furthermore, no difference in DFS and OS was found
in the 2 · 2 factorial GERCOR C96.1 study between 24 and 36
weeks of treatment as well as between LV5FU2 and monthly
bolus FU/LV.24
The feasibility of shorter treatment is of particular interest
with reference to the superior toxicity and efficacy of combi-
nation therapy.7. Biological therapy and future development
The response rate achieved in metastatic disease is com-
monly regarded as the best surrogate marker for the efficacy
of a given treatment as adjuvant treatment. The different out-
come of MOSAIC and PETACC-3 studies, however, suggests
that the activity of a regimen in advanced disease is not al-
ways a good predictor of its effect as adjuvant therapy. In
addition, as far as the biological agents are concerned, the
link between response rate in advanced disease and predicted
activity in adjuvant therapy is not necessarily reliable. Rather,the identification of predictive markers for the activity of bio-
logical agents might be a more appropriate prerequisite of
activity. In addition, if biological agents delay the manifesta-
tion of macrometastases rather than eliminate occult tumour
cells, the concept that 3-year DFS is a valid surrogate for 5-
year OS might not hold.
Despite the large diffusion of anti-EGFR and anti-VEGF
therapy in CRC, the knowledge of precise predictive markers
of their activity is limited. Recent reports supporting the link
between the activity of anti-EGFR antibodies and the absence
of K-RAS mutations or increased EGFR gene copies have in-
duced the regulatory authorities to consider the absence of
K-RAS mutations as a marker of susceptibility to anti-EGFR
therapy.25,26 On the other hand, the same widespread activity
of anti-VEGF therapy, irrespective of any known biological
marker, might raise some difficulty in classifying bev-
acizumab because it only indirectly targets the tumor. Given
the mechanism of action of bevacizumab, it is possible that
in adjuvant therapy an effect on DFSmight be observed rather
than on OS, unless a protracted VEGF inhibition leads to tu-
mour cell apoptosis.
Bevacizumab is currently evaluated in two large interna-
tional phase III trials in colon cancer adjuvant therapy
(AVANTand NSABP C-08), addressing the effect of adding bev-
acizumab to FOLFOX as well to CAPOX, and in a phase III
international adjuvant trial in rectal cancer (ECOG 5204).
Other two studies, involving bevacizumab (ECOG 5202 and
QUASAR-2), are restricted to high-risk stage II colon cancer.
Finally, a Italian study of GISCAD plans to evaluate the dura-
tion of treatment with FOLFOX (3 versus 6 months) in high-
risk stage II and in stage III patients as well as the addition
of bevacizumab to high-risk stage III patients.
Anti-EGFR antibodies target a tumour cell-bound antigen;
therefore, they may have some cytotoxic capability, but unfor-
tunately the response rate as single agent therapy in ad-
vanced disease is low and the benefit of adding an anti-
EGFR antibody to FOLFIRI o FOLFOX in the whole population
of almost two large phase III trials in advanced CTC is lower
than expected.27,28 Two trials in USA (IG/NCCTG-N0147) and
in Europe (PETACC-8) are currently under way to investigate
cetuximab in combination with FOLFOX.
At present, the clinical-pathologic stage represents the
only surrogate marker for the risk of distant micrometastatic
disease, but it has major limitations, as exemplified by the not
homogeneous prognosis of stage II as well as stage III pa-
tients. The use of agents that target biological pathways of tu-
mour cell or of its environment further reinforces the need of
carefully investigating on molecular prognostic factors. Most
ongoing trials planned a detailed study of potential biological
markers based on the existing knowledge. However, only few
trials have a design based on some known clinical–biological
prognostic/predictive factor. One of these studies is the ECOG
protocol E5202 which is enrolling patients with stage II colon
cancer with at least eight lymph nodes examined to exclude
metastases. In this protocol, the patients considered as hav-
ing high-risk disease on the basis of microsatellite instability
(MSI) and 18qLOH are randomised between OXA-based che-
motherapy with or without bevacizumab, whereas low risk
patients are assigned to observation only. At present, how-
ever, the prognostic value of MSI is still debated; therefore,
E J C S U P P L E M E N T S 6 ( 2 0 0 8 ) 6 0 –6 3 63it is uncertain whether this study will really allow us to iden-
tify the subgroup of high-risk patients.
In future, more precise predictive markers are expected
from the pharmacogenomic as well as prognostic grouping
would result from gene expression signature by means of
DNA-microarray that may allow to distinguish genetic pro-
files associated with prognosis and therapeutic outcome.
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